XBIT

XBiotech Inc. is a biopharmaceutical company. The Company is engaged in advancing a pipeline of therapies by harnessing naturally occurring antibodies from patients with immunity to certain diseases. The Company develops True Human monoclonal antibodies for treating a variety of diseases. True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance known as interleukin-1 alpha (IL-1a), which mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. IL-1a is a protein that is on or in cells of the body and is involved in the body’s response to injury or trauma, In almost all chronic and some acute injury scenarios (such as stroke or heart attack).